Skip to Content

Fenofibrate Dosage

Medically reviewed on March 31, 2017.

Applies to the following strengths: 48 mg; 145 mg; 54 mg; 160 mg; 67 mg; 200 mg; 134 mg; 40 mg; 120 mg; 43 mg; 130 mg; 30 mg; 90 mg; 50 mg; 150 mg

Usual Adult Dose for Hyperlipidemia

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIa (Elevated LDL)

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Dyslipidemia

Capsules: 150 mg orally once a day

Micronized Capsules: 90 to 200 mg orally once a day

Tablets: 120 to 160 mg orally once a day

Comments:
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Usual Adult Dose for Hyperlipoproteinemia Type IV (Elevated VLDL)

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Usual Adult Dose for Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Usual Adult Dose for Hypertriglyceridemia

Capsules:
-Initial dose: 50 to 150 mg orally per day
-Maximum dose: 150 mg once a day

Micronized Capsules:
-Initial dose: 30 to 200 mg orally per day
-Maximum dose: 90 to 200 mg/day

Tablets:
-Initial dose: 40 to 160 mg orally per day
-Maximum dose: 120 to 160 mg/day

Comments:
-Dosages should be individualized according to patient response and adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
-Therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment with the maximum recommended dose.

Use: As an adjunct to diet for the treatment of severe hypertriglyceridemia (Fredrickson Types IV and V)

Renal Dose Adjustments

Mild to moderate renal dysfunction:
-Capsules: 50 mg orally once a day
-Micronized Capsules: 30 to 67 mg orally once a day
-Tablets: 40 to 54 mg orally once a day; Triglide(R): Not recommended.

Comments:
-Doses may be increased after evaluation of the effects on renal function and lipid levels at the initial dose chosen.

Severe renal dysfunction: Contraindicated

Liver Dose Adjustments

Active liver disease (including primary biliary cirrhosis and unexplained persistent liver function abnormalities): Contraindicated

Dose Adjustments

Elderly: Due to the higher incidence of renal impairment in this patient population, dose selection should be based on renal function; monitor renal function during therapy; Lofibra(R) micronized capsules should be initiated and limited to 67 mg/day

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Contraindicated

Other Comments

Administration advice:
-May be taken with food to increase absorption.
-Swallow capsules and tablets whole; do not break, open, crush, dissolve, or chew.
-Take at least 1 hour before or 4 to 6 hours after a bile acid binding resin.

Storage requirements:
-Protect from light and moisture.
-Triglide(R): Dispense in original bottle.

General:
-Patients should be placed on an appropriate lipid-lowering diet prior to receiving this drug and should continue this diet throughout treatment.
-This drug has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.
-Markedly elevated levels of serum TG (e.g. greater than 2000 mg/dL) may increase the risk of developing pancreatitis; the effect of this drug on reducing this risk has not been adequately studied.
-An attempt should be made to control serum lipids with non-pharmacologic methods prior to initiating drug therapy (e.g., diet, exercise, control of medical problems, dose reduction of medications known to exacerbate hypertriglyceridemia, etc.).

Monitoring:
-Hematologic: Monitor RBC and WBC counts periodically during the first 12 months of therapy.
-Hepatic: Measure liver function at baseline and periodically thought-out therapy.
-Metabolic: Periodically measure lipid levels and adjust dose accordingly.
-Renal: Monitor renal function in patients with renal impairment or those at risk for renal insufficiency.

Patient advice:
-Report immediately any muscle pain, tenderness, or weakness, onset of abdominal pain, or any other new symptoms.
-Talk to your health care provider if you are pregnant, planning to become pregnant, or breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide